# Melanotan 2 References: The Cited Literature

> Melanotan 2 references — the full cited literature behind this digest, with PubMed links and DOIs: the human sexual-function trials, mechanism, pigmentation, safety.

## About these Melanotan 2 references

Every quantitative claim on this site maps to a numbered source below. The list leads with the human sexual-function and pigmentation studies, then the mechanism work, then the safety case reports and the regulatory and product-quality literature. Links resolve to PubMed; DOIs are given where available. This is the literature the digest is built from.

## References

[1] Dorr RT, Lines R, Levine N, Brooks C, Xiang L, Hruby VJ, Hadley ME. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sci. 1996;58(20):1777-1784. https://pubmed.ncbi.nlm.nih.gov/8637402/
[2] Wessells H, Fuciarelli K, Hansen J, Hadley ME, Hruby VJ, Dorr R, Levine N. Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study. J Urol. 1998;160(2):389-393. https://pubmed.ncbi.nlm.nih.gov/9679884/
[3] Hadley ME, Dorr RT. Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides. 2006;27(4):921-930. https://pubmed.ncbi.nlm.nih.gov/16412534/
[4] Peters B, Hadimeri H, Wahlberg R, Afghahi H. Melanotan II: a possible cause of renal infarction: review of the literature and case report. CEN Case Rep. 2020;9(2):159-161. https://pubmed.ncbi.nlm.nih.gov/31953620/
[5] Eliason NL, Martin L, Low MJ, Sharpe AL. Melanocortin receptor agonist melanotan-II microinjected in the nucleus accumbens decreases appetitive and consumptive responding for food. Neuropeptides. 2022;96:102289. https://pubmed.ncbi.nlm.nih.gov/36155088/
[6] Bonchev A. Changes in Oral Mucosa Associated with Melanotan II Injections: A Case Report. Life (Basel). 2026;16(2):265. https://pubmed.ncbi.nlm.nih.gov/41752902/
[7] Bloemers J, et al. Melanocortin 4 receptor agonism enhances sexual brain processing in women with hypoactive sexual desire disorder. J Clin Invest. 2022;132(19):e152341. https://pubmed.ncbi.nlm.nih.gov/36189794/
[8] Rossler AS, Pfaus JG, Kia HK, Bernabe J, Alexandre L, Giuliano F. The melanocortin agonist, melanotan II, enhances proceptive sexual behaviors in the female rat. Pharmacol Biochem Behav. 2006;85(3):514-521. https://pubmed.ncbi.nlm.nih.gov/17113634/
[9] Allard J, Giuliano F. Central nervous system agents in the treatment of erectile dysfunction: how do they work? Curr Urol Rep. 2001;2:488-494. https://pubmed.ncbi.nlm.nih.gov/12084236/
[10] Giuliano F, Clément P, Droupy S, Alexandre L, Bernabé J. Melanotan-II: investigation of the inducer and facilitator effects on penile erection in anaesthetized rat. Neuroscience. 2006;138:293-301. https://pubmed.ncbi.nlm.nih.gov/16360286/
[11] Biolcati G, Marchesini E, Sorge F, Barbieri L, Schneider-Yin X, Minder EI. Long-term observational study of afamelanotide in 115 patients with erythropoietic protoporphyria. Br J Dermatol. 2015;172(6):1601-1612. https://pubmed.ncbi.nlm.nih.gov/25494545/
[12] Ugwu SO, Blanchard J. High-performance liquid chromatographic assay for the alpha-melanotropin[4,10] fragment analogue (Melanotan-II) in rat plasma. J Chromatogr. 1992;584:175-180. https://pubmed.ncbi.nlm.nih.gov/1336500/
[13] Molinoff PB, Shadiack AM, Earle D, Diamond LE, Quon CY. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Ann N Y Acad Sci. 2003. (Reviewed in melanocortin sexual-dysfunction literature.) https://pubmed.ncbi.nlm.nih.gov/12851303/
[14] Lan KK, et al. Preformulation studies with melanotan-II: a potential skin cancer chemopreventive peptide. 1994. https://pubmed.ncbi.nlm.nih.gov/7983590/
[15] Strom MA, et al. Alpha-melanocyte stimulating hormone (alpha-MSH): biology, clinical relevance and implication in melanoma. J Transl Med. 2023;21(1):562. https://pubmed.ncbi.nlm.nih.gov/37608347/
[16] Cousen P, Colver G, Helbling I. Eruptive dysplastic nevi following melanotan use. 2012. https://pubmed.ncbi.nlm.nih.gov/22425244/
[17] Changes of melanocytic lesions induced by Melanotan injections and sun bed use in a teenage patient with FAMMM syndrome. 2012. https://pubmed.ncbi.nlm.nih.gov/23785612/
[18] Eruptive melanocytic naevi following melanotan injection. 2009. https://pubmed.ncbi.nlm.nih.gov/19575725/
[19] Cardones AR, Grichnik JM. alpha-Melanocyte-stimulating hormone-induced eruptive nevi. 2009. https://pubmed.ncbi.nlm.nih.gov/19380666/
[20] Eruptive naevi and darkening of pre-existing naevi 24 h after a single mono-dose injection of melanotan II. 2014. https://pubmed.ncbi.nlm.nih.gov/24334249/
[21] Melanotan-associated melanoma. 2011. https://pubmed.ncbi.nlm.nih.gov/21564053/
[22] Mazzarino M, et al. Barbie drug identification: not a child's play. J Forensic Sci. 2024. https://pubmed.ncbi.nlm.nih.gov/39302005/
[23] Dermoscopic changes in melanocytic nevi during use of melanotan II. 2012. https://pubmed.ncbi.nlm.nih.gov/23052015/
[24] Melanotan II injection resulting in systemic toxicity and rhabdomyolysis. 2012. https://pubmed.ncbi.nlm.nih.gov/23121206/
[25] Melanotan II overdose associated with priapism. 2013. https://pubmed.ncbi.nlm.nih.gov/23537392/
[26] Melanotan Tanning Injection: a rare cause of priapism. 2021. https://pubmed.ncbi.nlm.nih.gov/33460908/
[27] Melanotan-induced priapism: a hard-earned tan. 2019. https://pubmed.ncbi.nlm.nih.gov/30796078/
[28] Melanotan and the posterior reversible encephalopathy syndrome. 2013. https://pubmed.ncbi.nlm.nih.gov/23648958/
[29] Habbema L, et al. Risks of unregulated use of alpha-melanocyte-stimulating hormone analogues: a review. 2017. https://pubmed.ncbi.nlm.nih.gov/28266027/
[30] The unregulated use of melanotan-II is of public health interest to Australian dermatologists. 2017. https://pubmed.ncbi.nlm.nih.gov/28905366/
[31] Hemodynamic actions and mechanisms of systemically administered alpha-MSH analogs in mice. 2012. https://pubmed.ncbi.nlm.nih.gov/22982611/
[32] Systemic but not central nervous system nitric oxide synthase inhibition exacerbates the hypertensive effects of chronic melanocortin-3/4 receptor activation. 2011. https://pubmed.ncbi.nlm.nih.gov/21263126/
[33] Melanotan II User Experience: A Qualitative Study of Online Discussion Forums. 2021. https://pubmed.ncbi.nlm.nih.gov/34464955/
[34] The 'Barbie Drug'—marketing and perceptions of melanotan on social media. 2025. https://pubmed.ncbi.nlm.nih.gov/38808957/
[35] Identification and characterization by LC-UV-MS/MS of melanotan II skin-tanning products sold illegally on the Internet. 2015. https://pubmed.ncbi.nlm.nih.gov/24771717/
[36] LC-HRMS characterization of the skin pigmentation and sexual enhancers melanotan II and bremelanotide sold on the black market of performance and image enhancing drugs. 2021. https://pubmed.ncbi.nlm.nih.gov/33245851/
[37] Melanotropic peptides: more than just 'Barbie drugs' and 'sun-tan jabs'? 2010. https://pubmed.ncbi.nlm.nih.gov/20545686/

---

A charcoal instrument-cluster reading of the Melanotan 2 record — the sexual-function trials logged first, the half-life and receptor data stated as plain gauge values, the priapism, kidney and changing-mole case reports flagged in plain sight; no clinic behind the console and nothing here dosed, injected, prescribed, or sold.